BRAF and thyroid cancer: Lapatinib as a small molecule dual tyrosine kinase inhibitor of EGFR and HER-2 has been demonstrated the ability to prevent the rebound of the ERK signaling and sensitize BRAF-mutant thyroid cancer cells to RAF or MEK inhibitors [10].